Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MASP2 | O00187 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702265 | 1.00 | RXFP1 (0.55) | RXFP1KMT2AMASP2POLBKDM4E | |
| SCHEMBL30173444 | 0.87 | KMT2A (0.54) | RXFP1KMT2AMASP2POLBKDM4E | |
| SCHEMBL1690938 | 0.87 | KMT2A (0.54) | RXFP1KMT2AMASP2POLBKDM4E | |
| SCHEMBL29992092 | 0.87 | RXFP1 (0.59) | RXFP1KMT2APOLBLMNAMEN1 | |
| SCHEMBL15368377 | 0.87 | RXFP1 (0.59) | RXFP1KMT2APOLBLMNAMEN1 | |
| SCHEMBL29663621 | 0.87 | RXFP1 (0.55) | RXFP1KMT2APOLBKDM4ELMNA | |
| SCHEMBL5812852 | 0.86 | KDM4E (0.51) | RXFP1KMT2APOLBKDM4ELMNA | |
| SCHEMBL3248129 | 0.86 | NPC1 (0.54) | RXFP1KMT2AKDM4ELMNAMEN1 | |
| SCHEMBL2703465 | 0.86 | ALDH1A1 (0.54) | RXFP1KMT2APOLBLMNABRD9 | |
| SCHEMBL2880191 | 0.86 | LMNA (0.54) | RXFP1KMT2APOLBCA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567537-A | Synthesis and use of reversible termination nucleotide based on pH sensitive connecting unit | 上海交通大学 | 2024-02-20 | — | — | CN | claimed |
| US-20020019013-A1 | Combined resin method for high-speed synthesis of combinatorial libraries | ADVANCED SYNTECH, LLC | 2002-02-14 | — | — | US | claimed |
| EP-4746966-A1 | 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2026-05-27 | — | — | EP | disclosed |
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2026-04-09 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250376711-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | URTESTE S.A. (PL) | 2025-12-11 | — | — | US | disclosed |
| EP-4649167-A2 | COMPOUND - DIAGNOSTIC MARKER FOR BILIARY TRACT CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF BILIARY TRACT CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF BILIARY TRACT CANCER | Urteste S.A. (PL) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025216642-A1 | ENZYMATIC ACTIVITY BASED METHOD AND MARKER FOR THE DIAGNOSIS OF BRAIN TUMOUR | URTESTE S.A. (PL) | 2025-10-16 | — | — | WO | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250270617-A1 | Compound - diagnostic marker for kidney cancer, method for detecting enzymatic activity, method for diagnosis of kidney cancer, kit comprising the compound, uses of the compound and method for the treatment of kidney cancer | URTESTE S.A. (PL) | 2025-08-28 | — | — | US | disclosed |
| WO-1996033209-A1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF PRO-APOPTOTIC CYSTEINE PROTEINASES | MERCK FROSST CANADA INC. (CA) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996033268-A1 | APOPAIN | MERCK & CO., INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0528854-B1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG AS (DK) | 1994-12-28 | — | — | EP | disclosed |
| EP-0625978-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| US-5298409-A | Of esters, antigen diastereomers which are stable analogs of the unstable ester transition states | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-29 | — | — | US | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| EP-0528854-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES. | CARLSBERG AS (DK) | 1993-03-03 | — | — | EP | disclosed |
| US-5190865-A | Antibody-enhanced stereospecific hydrolyses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-03-02 | — | — | US | disclosed |
| WO-1991016336-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG A/S (DK) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019013-A1 | Combined resin method for high-speed synthesis of combinatorial libraries | CPSF1, CPSF6, PLAU | RXFP1 2819/4885KMT2A 1951/4885MASP2 246/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | RXFP1 2737/4885KMT2A 1229/4885MASP2 4799/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | RXFP1 2676/4885KMT2A 3331/4885MASP2 2132/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | RXFP1 4124/4885KMT2A 932/4885MASP2 4167/4885 |
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | DNPEP, ANPEP, CA9 | RXFP1 2731/4885KMT2A 3068/4885MASP2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.